# Sense Biodetection

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sense-biodetection

- Industry: Medical Devices & Equipment
- Headquarters: Abingdon, UK
- Website: www.sense-bio.com
- Total disclosed funding: $79M
- Latest round: Series B (Nov 17, 2021)
- Investors on record: 4

## About

Based in the UK, Sense Biodetection Limited specializes in developing advanced diagnostic solutions for healthcare providers, focusing on rapid and accurate detection technologies that enhance health outcomes across various settings.Sense Biodetection Limited, founded in 2014 in Abingdon, UK, is focused on developing innovative diagnostic tools. The company was acquired by Sherlock Biosciences, Inc. in February 2023, enhancing their go-to-market strategy with new manufacturing capabilities. Harry Lamble is the CEO of Sense Biodetection. The company has raised a total of USD 15.00 mn through its latest funding round, Series B, led by Koch Disruptive Technologies. This represents all the capital raised to date, with a total of 6 deals completed by the firm, the most recent being in 2023.Sense Biodetection, now part of OraSure Technologies, focuses on biotechnology solutions, specifically advanced diagnostic tools that facilitate efficient disease detection. Their products are designed for healthcare providers, laboratories, and clinical environments, ensuring rapid testing capabilities aimed at improving health outcomes. Sense Biodetection targets both local and international markets, including North America, Europe, and select regions in Asia, providing versatile applications within the healthcare sector.In 2023, Sense Biodetection reported zero revenue, with an EBITDA of USD -34,755,017.70, indicating operational challenges that need addressing for future sustainability.Following the acquisition by Sherlock Biosciences, Inc. in February 2023, Sense Biodetection plans to leverage its rapid molecular test platform to enhance product offerings. The integration will focus on expanding manufacturing capabilities and entering new markets by deploying innovative products. The recent funding will support these strategic objectives to optimize their market presence and develop new diagnostic solutions.

## Funding rounds

- Series B, Nov 17, 2021, $15M — Koch Disruptive Technologies
- Series B, Apr 20, 2021, $50M — Mercia Asset Management, Earlybird, Cambridge Innovation Capital, Koch Disruptive Technologies
- Series B, Jul 19, 2019, $13M — Mercia Asset Management, Earlybird, Cambridge Innovation Capital
- Seed, Mar 30, 2016, $0.7M — Mercia Asset Management

## Investors

- Mercia Asset Management (https://capitalatlas.ai/funds/mercia-asset-management) — Seed, Series B
- Earlybird (https://capitalatlas.ai/funds/earlybird) — Series B
- Cambridge Innovation Capital (https://capitalatlas.ai/funds/cambridge-innovation-capital) — Series B
- Koch Disruptive Technologies (https://capitalatlas.ai/funds/koch-disruptive-technologies) — Series B